Developer docs
API playgroundTry for free, no card

Search company profiles

Ainnova Tech

Full company profile

uuid00007a9

Namestring
Ainnova Tech
Legal namestring
Ainnova Tech Inc.
Websiteurl
ainnovatech.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Ainnova Tech is a Nevada-registered health technology company, founded in 2020 and headquartered in San José, Costa Rica with a U.S. base in Houston, Texas and operations in Mexico City. The company has built VisionAI, a web-based AI platform that analyzes high-resolution retinal fundus images (captured via non-mydriatic cameras) to enable early detection of multiple diseases from a single non-invasive scan. Its clinically validated modules include diabetic retinopathy screening (>90% accuracy, in FDA pre-submission), a cardiovascular risk score (AICVD, validated by Apollo Hospitals on 2.3M+ data points), a prediabetes/type 2 diabetes risk model built on 40,000+ patient records using XGBoost (AUC 0.86), an AI liver fibrosis risk score (AUC 0.88), and a chronic kidney disease progression model (>85% accuracy). Active R&D targets age-related macular degeneration, glaucoma, and Alzheimer's detection, and the company holds a patented early-stage dementia detection technology.

The VisionAI platform is paired with proprietary Versatile Retinal Cameras and is commercialized through a multi-channel strategy: a joint venture with Avant Technologies (Ai-nova Acquisition Corp) for North America and Europe; an exclusive AI algorithm license and clinical collaboration with Apollo Hospitals for hospital-channel deployment across the Americas; direct distribution to opticians and eye care centers in Costa Rica, Mexico, Chile, and the Dominican Republic; and the recently acquired OTCHealth Inc., which brings agreements with major U.S. pharmacy chains. The revenue model is subscription / recurring platform licensing to medical facilities for preventive screening; pricing is quote-based and not publicly disclosed.

The company is small (1–10 employees) and pre-IPO, with stated intent to go public in 2025 and a pending full acquisition by Avant Technologies. Cumulative disclosed funding is approximately $5.8M across 2022–2025; no revenue is publicly disclosed. Commercial activity is currently concentrated in Latin American pilots, with FDA 510(k) clearance, ANVISA approval for Brazil, and U.S. retail pharmacy scaling through OTCHealth positioned as the principal near-term growth catalysts.

Short descriptiontext

Ainnova Tech is a Nevada-registered health tech company that builds VisionAI, an AI platform analyzing retinal images for early detection of diabetic retinopathy, cardiovascular risk, prediabetes, liver fibrosis, and chronic kidney disease. It serves opticians, clinics, hospitals, and pharmacies across the Americas through partnerships and licensing.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersHouston, United States
HQ citystring
Houston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI diagnostics, retinal imaging, diabetic retinopathy screening, preventive healthcare, medical imaging software
Industry5 codes
PRIMARYHLAHAJAB
Retinal Imaging & OCT Systems (OCT/OCTA, Fundus Cameras, Fluorescein/ICG Angiography)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLAKAKAN
Ocular Imaging & Diagnostic Testing Centers
SECONDARYHLAFAKAI
Vision & Ophthalmic Diagnostic Centers (Optometry/OCT/Retinal Imaging)
SECONDARYHLAKAKAE
Retina & Vitreous Specialists
SECONDARYHLAHAJAN
Low Vision & Assistive Vision Devices (Magnifiers, Electronic Video Magnifiers, Wearable Vision Aids)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
NAICS code4 codes
  • Ophthalmic Goods Manufacturing339115
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing33451
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing3345
  • Surgical and Medical Instrument Manufacturing339112
SIC code3 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Electromedical & Electrotherapeutic Apparatus3845
  • Ophthalmic Goods3851
Product category
AI Medical Imaging Diagnostics
No data
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1VisionAI Platform Licensing
TypeSubscription Recurring
Description

AI-powered diagnostic platform for early disease detection licensed to healthcare providers, opticians, and eye care centers. Revenue generated through platform licensing to medical facilities using the technology for preventive screening.

globenewswire.com
2Diagnostic Screening Services
TypeSubscription Recurring
Description

AI-powered screening solutions delivered to primary care, pharmacies, and wellness centers. Non-invasive fundus eye tests and multi-disease risk assessments for preventive healthcare.

ainnovatech.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 5 records shown
1VisionAI Platform
Description

AI-powered platform for early disease detection including diabetic retinopathy, cardiovascular risk assessment, type 2 diabetes risk, liver fibrosis detection, and chronic kidney disease progression.

ainnovatech.com
+4 more records
Core offering1 text field

Ainnova Tech develops and sells VisionAI, an AI-powered software platform that analyzes non-mydriatic retinal fundus images to detect diabetic retinopathy and other retinal diseases, delivering results in seconds with over 90% diagnostic accuracy. The platform extends beyond retinal screening with additional AI risk models for cardiovascular disease (AICVD), type 2 diabetes, liver fibrosis, and chronic kidney disease progression, validated against Apollo Hospitals' 2.3M+ data points. The company also develops proprietary Versatile Retinal Cameras and pursues FDA 510(k) clearance for U.S. commercialization while distributing through healthcare providers, opticians, eye care centers, hospital systems, and retail pharmacies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Over 90% diagnostic accuracy for diabetic retinopathy detection
+5 more records
Product overview1 text field

Ainnova Tech offers VisionAI, a unified AI-powered healthcare platform designed for early disease detection. The core platform centers on diabetic retinopathy screening through retinal fundus imaging, augmented by multiple AI-driven risk assessment modules including cardiovascular disease (AICVD Cardiac Risk Score), type 2 diabetes (Prediabetes AI Risk Assessment), liver fibrosis (AI Liver Fibrosis Risk Score), and chronic kidney disease (CKD Progression Risk Model). The company also develops proprietary Versatile Retinal Cameras. Active R&D efforts target Alzheimer's disease and additional eye conditions (AMD, glaucoma) detection. The company operates through partnerships including a joint venture with Avant Technologies (Ai-nova Acquisition Corp) for North America and Europe commercialization, and a strategic collaboration with Apollo Hospitals for AI algorithm development.

Product and service1 record
1VisionAI Platform
Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-22
Description

Strategic alliance in Ainnova Tech's pending acquisition of OTCHealth Inc. InnerScope is leveraging its retail agreements and technology pipeline to expand reach and foster innovation in hearing health and preventive healthcare. Transaction involves transfer of retail operations including agreements with major U.S. pharmacy chains to OTCHealth, now a subsidiary of Ainnova.

2OTCHealth Inc.
Strategic tierCoreTypeOthersAnnounced on2025-10-22
Description

Pending acquisition target. Retail operations including agreements with major U.S. pharmacy chains being transferred to OTCHealth, now a subsidiary of Ainnova Tech. Enables national retail reach for hearing health and preventive healthcare products.

marketscreener.com
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-03-10
Description

Strategic collaboration with Apollo Hospitals securing exclusive license for AI algorithms validated with over 2.3 million data points. Commercial pilot programs launching across the Americas with expansion planned for Brazil pending ANVISA regulatory approval. Deployment for early detection of cardiovascular disease, chronic kidney disease, liver fibrosis, type 2 diabetes, and lung abnormalities.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2024-11-12
Description

Formed joint venture through Ai-nova Acquisition Corp to commercialize Ainnova's VisionAI platform and retinal camera technology for early disease detection across North America and Europe. Partnership leverages Avant's capital investment to scale AI-powered diagnostic solutions including diabetic retinopathy screening and cardiovascular risk assessment through opticians and eye care centers. Avant is pursuing full acquisition of Ainnova Tech.

5Zappy Zapolin (Board Advisor)
Strategic tierMinorTypeOthersAnnounced on2024-08-30
Description

Renowned entrepreneur and visionary joins Ainnova's Board of Advisors bringing decades of experience in strategic leadership, innovation, and brand development.

ainnovatech.com
6Ian K. Gordon (Board Advisor)
Strategic tierMinorTypeOthersAnnounced on2024-07-30
Description

Over 30 years of diverse experience in U.S. healthcare system with key roles in operations, technology, and strategy at major healthcare organizations. Joins Board of Advisors.

ainnovatech.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-06-01
Description

Collaboration to create AI-powered affordable imaging device for early disease detection. Highlights commitment to revolutionizing retinal image capture and providing accessible solutions for early-stage disease detection.

8Marcus Dantus (Board Advisor)
Strategic tierMinorTypeOthersAnnounced on2022-10-06
Description

Shark of TV Show Shark Tank Mexico joins as board advisor to drive growth and global expansion strategy.

ainnovatech.com
9Manuel Zuñiga (Board Member) and Chad Harman (Board Director)
Strategic tierMinorTypeOthersAnnounced on2022-03-23
Description

Manuel Zuñiga appointed as board member and Chad Harman as board director to fortify leadership team.

ainnovatech.com
Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Direct competitor offering EyeArt, an FDA-cleared AI system for autonomous detection of diabetic retinopathy from retinal fundus images. Closest comparable on core product, target customer (primary care, optometry, retail optical), and regulatory pathway.

2Digital Diagnostics (IDx)
TypeDirect peer
Description

Pioneer of IDx-DR, the first FDA-authorized autonomous AI diagnostic system for diabetic retinopathy, now part of Topcon Healthcare. Directly competes with VisionAI in retail optical and primary care DR screening channels.

TypeDirect peer
Description

AEYE-DS is an FDA-cleared AI for diabetic retinopathy screening from a single retinal image, targeted at primary care and retail pharmacy settings. Highly comparable in product scope, deployment model, and customer segments.

TypeDirect peer
Description

European-based AI vendor for retinal image analysis (DR, AMD, glaucoma), offering screening tools to opticians and primary care. Comparable in applying AI to non-mydriatic retinal images for early disease detection.

TypeBroad incumbent
Description

Acquired Digital Diagnostics (IDx) and is building a broad AI-driven eye-care platform across retinal imaging hardware, screening software, and integrated care pathways. Wider portfolio than Ainnova, but the AI screening module competes head-on with VisionAI.

TypeBroad incumbent
Description

Manufacturer of ultra-widefield retinal imaging hardware (optomap), now part of Nikon Healthcare. Comparable as a retinal-imaging vendor whose installed base of cameras is a deployment surface for DR/disease-screening AI software like VisionAI.

7Carl Zeiss Meditec
TypeBroad incumbent
Description

Major ophthalmic device manufacturer with a broad portfolio of retinal imaging systems (OCT, fundus cameras) used by the same optometry/ophthalmology customers that Ainnova targets with VisionAI. Encompasses the imaging hardware ecosystem in which Ainnova's software sits.

8Nanox (formerly Zebra Medical Vision)
TypeEmerging player
Description

AI imaging diagnostics company with multi-disease AI algorithms on radiology (and historically CT/mammography) imaging; comparable as a multi-condition AI diagnostics platform with regulatory ambition, but anchored in radiology rather than retinal imaging.

9Tempus Labs
TypeEmerging player
Description

AI-driven precision medicine company applying machine learning to clinical and molecular data for disease risk and treatment prediction. Comparable as an AI platform that derives multiple disease-risk models (cardiovascular, oncology) from clinical inputs, mirroring VisionAI's multi-condition approach.

TypeOthers
Description

Commercial-stage AI diagnostics company that derives cardiovascular disease risk from imaging data (CT angiography). Comparable as a peer in AI-driven cardiovascular risk assessment — directly relevant to Ainnova's AICVD Cardiac Risk Score module.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ainnova Tech

AI Medical Imaging Diagnosticsainnovatech.com

Ainnova Tech is a Nevada-registered health tech company that builds VisionAI, an AI platform analyzing retinal images for early detection of diabetic retinopathy, cardiovascular risk, prediabetes, liver fibrosis, and chronic kidney disease. It serves opticians, clinics, hospitals, and pharmacies across the Americas through partnerships and licensing.

What Ainnova Tech does

Ainnova Tech is a Nevada-registered health technology company, founded in 2020 and headquartered in San José, Costa Rica with a U.S. base in Houston, Texas and operations in Mexico City. The company has built VisionAI, a web-based AI platform that analyzes high-resolution retinal fundus images (captured via non-mydriatic cameras) to enable early detection of multiple diseases from a single non-invasive scan. Its clinically validated modules include diabetic retinopathy screening (>90% accuracy, in FDA pre-submission), a cardiovascular risk score (AICVD, validated by Apollo Hospitals on 2.3M+ data points), a prediabetes/type 2 diabetes risk model built on 40,000+ patient records using XGBoost (AUC 0.86), an AI liver fibrosis risk score (AUC 0.88), and a chronic kidney disease progression model (>85% accuracy). Active R&D targets age-related macular degeneration, glaucoma, and Alzheimer's detection, and the company holds a patented early-stage dementia detection technology.

The VisionAI platform is paired with proprietary Versatile Retinal Cameras and is commercialized through a multi-channel strategy: a joint venture with Avant Technologies (Ai-nova Acquisition Corp) for North America and Europe; an exclusive AI algorithm license and clinical collaboration with Apollo Hospitals for hospital-channel deployment across the Americas; direct distribution to opticians and eye care centers in Costa Rica, Mexico, Chile, and the Dominican Republic; and the recently acquired OTCHealth Inc., which brings agreements with major U.S. pharmacy chains. The revenue model is subscription / recurring platform licensing to medical facilities for preventive screening; pricing is quote-based and not publicly disclosed.

The company is small (1–10 employees) and pre-IPO, with stated intent to go public in 2025 and a pending full acquisition by Avant Technologies. Cumulative disclosed funding is approximately $5.8M across 2022–2025; no revenue is publicly disclosed. Commercial activity is currently concentrated in Latin American pilots, with FDA 510(k) clearance, ANVISA approval for Brazil, and U.S. retail pharmacy scaling through OTCHealth positioned as the principal near-term growth catalysts.

Ainnova Tech firmographics

Firmographics
Name
Ainnova Tech
Legal name
Ainnova Tech Inc.
Website
https://ainnovatech.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
1–10 employees
Short description
Ainnova Tech is a Nevada-registered health tech company that builds VisionAI, an AI platform analyzing retinal images for early detection of diabetic retinopathy, cardiovascular risk, prediabetes, liver fibrosis, and chronic kidney disease. It serves opticians, clinics, hospitals, and pharmacies across the Americas through partnerships and licensing.
Ownership category
akta.pro rank

Ainnova Tech industry classification

Industry
Product category
AI Medical Imaging Diagnostics
NAICS
Ophthalmic Goods Manufacturing (339115), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345), Surgical and Medical Instrument Manufacturing (339112)
SIC
Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845), Ophthalmic Goods (3851)
akta.pro industry
PRIMARYHLAHAJAB
Retinal Imaging & OCT Systems (OCT/OCTA, Fundus Cameras, Fluorescein/ICG Angiography)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLAKAKAN
Ocular Imaging & Diagnostic Testing Centers
SECONDARYHLAFAKAI
Vision & Ophthalmic Diagnostic Centers (Optometry/OCT/Retinal Imaging)
SECONDARYHLAKAKAE
Retina & Vitreous Specialists
SECONDARYHLAHAJAN
Low Vision & Assistive Vision Devices (Magnifiers, Electronic Video Magnifiers, Wearable Vision Aids)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)

Keywords

  • AI diagnostics
  • Retinal imaging
  • Diabetic retinopathy screening
  • Preventive healthcare
  • Medical imaging software

Where Ainnova Tech is headquartered

Location

Headquarters

HQ city
Houston
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Ainnova Tech business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. VisionAI Platform Licensing: AI-powered diagnostic platform for early disease detection licensed to healthcare providers, opticians, and eye care centers. Revenue generated through platform licensing to medical facilities using the technology for preventive screening.
  2. Diagnostic Screening Services: AI-powered screening solutions delivered to primary care, pharmacies, and wellness centers. Non-invasive fundus eye tests and multi-disease risk assessments for preventive healthcare.

Go-to-market motion3 records

Distribution channels5 records

Marketing channels4 records

Ainnova Tech product offering

Product offering

Core offering

Ainnova Tech develops and sells VisionAI, an AI-powered software platform that analyzes non-mydriatic retinal fundus images to detect diabetic retinopathy and other retinal diseases, delivering results in seconds with over 90% diagnostic accuracy. The platform extends beyond retinal screening with additional AI risk models for cardiovascular disease (AICVD), type 2 diabetes, liver fibrosis, and chronic kidney disease progression, validated against Apollo Hospitals' 2.3M+ data points. The company also develops proprietary Versatile Retinal Cameras and pursues FDA 510(k) clearance for U.S. commercialization while distributing through healthcare providers, opticians, eye care centers, hospital systems, and retail pharmacies.

Product overview

Ainnova Tech offers VisionAI, a unified AI-powered healthcare platform designed for early disease detection. The core platform centers on diabetic retinopathy screening through retinal fundus imaging, augmented by multiple AI-driven risk assessment modules including cardiovascular disease (AICVD Cardiac Risk Score), type 2 diabetes (Prediabetes AI Risk Assessment), liver fibrosis (AI Liver Fibrosis Risk Score), and chronic kidney disease (CKD Progression Risk Model). The company also develops proprietary Versatile Retinal Cameras. Active R&D efforts target Alzheimer's disease and additional eye conditions (AMD, glaucoma) detection. The company operates through partnerships including a joint venture with Avant Technologies (Ai-nova Acquisition Corp) for North America and Europe commercialization, and a strategic collaboration with Apollo Hospitals for AI algorithm development.

Differentiator

Problem solved

Functional benefit

Brands

  • VisionAI Platform: AI-powered platform for early disease detection including diabetic retinopathy, cardiovascular risk assessment, type 2 diabetes risk, liver fibrosis detection, and chronic kidney disease progression.
  • AICVD Cardiac Risk Score
  • Prediabetes AI Risk Assessment
  • AI Liver Fibrosis Risk Score
  • CKD Progression Risk Model

Products and services

  • VisionAI Platform

Quantifiable outcome

  • Over 90% diagnostic accuracy for diabetic retinopathy detection
  • +5 more outcomes

Companies that use Ainnova Tech

Customer profile

Named customers5 records

Segments6 records

Ideal customer profiles4 records

Ainnova Tech technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature8 records

Ainnova Tech partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core, flagship and minor.

  • InnerScope Hearing TechnologiescoreStrategic or Co-development Partner · 22 October 2025Strategic alliance in Ainnova Tech's pending acquisition of OTCHealth Inc. InnerScope is leveraging its retail agreements and technology pipeline to expand reach and foster innovation in hearing health and preventive healthcare. Transaction involves transfer of retail operations including agreements with major U.S. pharmacy chains to OTCHealth, now a subsidiary of Ainnova.
  • OTCHealth Inc.coreOthers · 22 October 2025Pending acquisition target. Retail operations including agreements with major U.S. pharmacy chains being transferred to OTCHealth, now a subsidiary of Ainnova Tech. Enables national retail reach for hearing health and preventive healthcare products.
  • Apollo HospitalscoreTechnology or Integration · 10 March 2025Strategic collaboration with Apollo Hospitals securing exclusive license for AI algorithms validated with over 2.3 million data points. Commercial pilot programs launching across the Americas with expansion planned for Brazil pending ANVISA regulatory approval. Deployment for early detection of cardiovascular disease, chronic kidney disease, liver fibrosis, type 2 diabetes, and lung abnormalities.
  • Avant TechnologiesflagshipStrategic or Co-development Partner · 12 November 2024Formed joint venture through Ai-nova Acquisition Corp to commercialize Ainnova's VisionAI platform and retinal camera technology for early disease detection across North America and Europe. Partnership leverages Avant's capital investment to scale AI-powered diagnostic solutions including diabetic retinopathy screening and cardiovascular risk assessment through opticians and eye care centers. Avant is pursuing full acquisition of Ainnova Tech.
  • Zappy Zapolin (Board Advisor)minorOthers · 30 August 2024Renowned entrepreneur and visionary joins Ainnova's Board of Advisors bringing decades of experience in strategic leadership, innovation, and brand development.
  • Ian K. Gordon (Board Advisor)minorOthers · 30 July 2024Over 30 years of diverse experience in U.S. healthcare system with key roles in operations, technology, and strategy at major healthcare organizations. Joins Board of Advisors.
  • ITEKminorStrategic or Co-development Partner · 1 June 2024Collaboration to create AI-powered affordable imaging device for early disease detection. Highlights commitment to revolutionizing retinal image capture and providing accessible solutions for early-stage disease detection.
  • Marcus Dantus (Board Advisor)minorOthers · 6 October 2022Shark of TV Show Shark Tank Mexico joins as board advisor to drive growth and global expansion strategy.
  • Manuel Zuñiga (Board Member) and Chad Harman (Board Director)minorOthers · 23 March 2022Manuel Zuñiga appointed as board member and Chad Harman as board director to fortify leadership team.

Scale indicators13 records

Recent moves10 records

Expansion highlights6 records

Ainnova Tech competitors and assessment

Company assessment

Direct peers

  • Eyenuk: Direct competitor offering EyeArt, an FDA-cleared AI system for autonomous detection of diabetic retinopathy from retinal fundus images. Closest comparable on core product, target customer (primary care, optometry, retail optical), and regulatory pathway.
  • Digital Diagnostics (IDx): Pioneer of IDx-DR, the first FDA-authorized autonomous AI diagnostic system for diabetic retinopathy, now part of Topcon Healthcare. Directly competes with VisionAI in retail optical and primary care DR screening channels.
  • AEYE Health: AEYE-DS is an FDA-cleared AI for diabetic retinopathy screening from a single retinal image, targeted at primary care and retail pharmacy settings. Highly comparable in product scope, deployment model, and customer segments.
  • RetinaLyze: European-based AI vendor for retinal image analysis (DR, AMD, glaucoma), offering screening tools to opticians and primary care. Comparable in applying AI to non-mydriatic retinal images for early disease detection.

Broad incumbents

  • Topcon Healthcare: Acquired Digital Diagnostics (IDx) and is building a broad AI-driven eye-care platform across retinal imaging hardware, screening software, and integrated care pathways. Wider portfolio than Ainnova, but the AI screening module competes head-on with VisionAI.
  • Optos: Manufacturer of ultra-widefield retinal imaging hardware (optomap), now part of Nikon Healthcare. Comparable as a retinal-imaging vendor whose installed base of cameras is a deployment surface for DR/disease-screening AI software like VisionAI.
  • Carl Zeiss Meditec: Major ophthalmic device manufacturer with a broad portfolio of retinal imaging systems (OCT, fundus cameras) used by the same optometry/ophthalmology customers that Ainnova targets with VisionAI. Encompasses the imaging hardware ecosystem in which Ainnova's software sits.

Emerging players

  • Nanox (formerly Zebra Medical Vision): AI imaging diagnostics company with multi-disease AI algorithms on radiology (and historically CT/mammography) imaging; comparable as a multi-condition AI diagnostics platform with regulatory ambition, but anchored in radiology rather than retinal imaging.
  • Tempus Labs: AI-driven precision medicine company applying machine learning to clinical and molecular data for disease risk and treatment prediction. Comparable as an AI platform that derives multiple disease-risk models (cardiovascular, oncology) from clinical inputs, mirroring VisionAI's multi-condition approach.

Others

  • HeartFlow: Commercial-stage AI diagnostics company that derives cardiovascular disease risk from imaging data (CT angiography). Comparable as a peer in AI-driven cardiovascular risk assessment — directly relevant to Ainnova's AICVD Cardiac Risk Score module.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Ainnova Tech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ainnova Tech leadership team

Management profile

Number of profiles

Profiles13 records

Ainnova Tech subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Ainnova Tech funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ainnova Tech M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ainnova Tech

What does Ainnova Tech do?

Ainnova Tech develops and sells VisionAI, an AI-powered software platform that analyzes non-mydriatic retinal fundus images to detect diabetic retinopathy and other retinal diseases, delivering results in seconds with over 90% diagnostic accuracy. The platform extends beyond retinal screening with additional AI risk models for cardiovascular disease (AICVD), type 2 diabetes, liver fibrosis, and chronic kidney disease progression, validated against Apollo Hospitals' 2.3M+ data points. The company also develops proprietary Versatile Retinal Cameras and pursues FDA 510(k) clearance for U.S. commercialization while distributing through healthcare providers, opticians, eye care centers, hospital systems, and retail pharmacies.

Is Ainnova Tech a public or private company?

Ainnova Tech is a private company. It is classified as venture growth investor backed and is currently operating.

When was Ainnova Tech founded?

Ainnova Tech was founded in 2020. It employs 1 to 10 people.

Where is Ainnova Tech based?

Ainnova Tech is headquartered in Houston, United States, in the North America region.

How does Ainnova Tech make money?

Two revenue lines are on record. VisionAI Platform Licensing is the primary driver. The others are diagnostic Screening Services.

Who are Ainnova Tech's main competitors?

Direct peers on record are Eyenuk, Digital Diagnostics (IDx), AEYE Health and RetinaLyze. Broad incumbents are Topcon Healthcare, Optos and Carl Zeiss Meditec. Emerging players are Nanox (formerly Zebra Medical Vision) and Tempus Labs. HeartFlow is listed as an others.

Does Ainnova Tech have an API?

No public API is recorded for Ainnova Tech.

What industry is Ainnova Tech in?

Ainnova Tech's product category is AI Medical Imaging Diagnostics. Its primary akta.pro industry code is HLAHAJAB, Retinal Imaging & OCT Systems (OCT/OCTA, Fundus Cameras, Fluorescein/ICG Angiography), with a secondary code of HLAKAKAN, Ocular Imaging & Diagnostic Testing Centers. Its NAICS code is 339115 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireGlobal AI in Medical Diagnostics Market Poised for Phenomenal Expansion at a CAGR of ~22% by 2032 | DelveInsightDelveInsight published a market research report projecting the global AI in medical diagnostics market to grow from USD 1.6 billion in 2024 to approximately USD 8 billion by 2032, representing a CAGR of ~22% during the forecast period (2025–2032). Key recent developmental activities include Roche receiving FDA Breakthrough Device Designation for its VENTANA TROP2 companion diagnostic in April 2025, and Avant Technologies partnering with Ainnova Tech on an FDA-reviewed VisionAI platform. North America, led by the U.S., held a 51% market share in 2024, driven by rising chronic disease prevalence, advanced R&D infrastructure, and expedited regulatory approvals.PR NewswireInnerScope Hearing Technologies Forms Strategic Alliance in Ainnova Tech's Acquisition of OTCHealth Inc., Unlocking National Retail Reach and Accelerating Global Hearing InnovationInnerScope Hearing Technologies announced its strategic role in the pending acquisition of OTCHealth Inc. by Ainnova Tech Inc., with InnerScope transferring its U.S. retail sales operations—including agreements with Walmart, CVS, Target, Walgreens, and 15,000+ independent pharmacies—to OTCHealth. In exchange, InnerScope will receive equity and profit participation in both OTCHealth and Ainnova Tech post-acquisition. The alliance aims to integrate InnerScope's hearing healthcare expertise with Ainnova's AI-powered early disease detection platform to deliver preventive health solutions to millions of consumers nationwide.MarketScreenerInnerScope Hearing Technologies Forms Strategic Alliance in Ainnova Tech's Acquisition of OTCHealth Inc., Unlocking National Retail Reach and Accelerating Global Hearing InnovationInnerScope Hearing Technologies announced its strategic role in Ainnova Tech's pending acquisition of OTCHealth Inc., where InnerScope will transition its U.S. retail sales operations—including agreements with Walmart, CVS, Target, Walgreens, and 15,000+ independent pharmacies—to OTCHealth. As part of the transaction, InnerScope will receive equity and profit participation in both OTCHealth and Ainnova Tech, while focusing on global R&D and technology innovation. The alliance aims to combine InnerScope's hearing healthcare expertise with Ainnova's AI diagnostics platform to enable earlier identification of health conditions.FinansavisenHealthcare AI Market Explodes 38.5% Annually as Diagnostics Gain FDA TractionThe global AI healthcare market is forecast to reach nearly $700 billion by 2034, growing at a 38.5% CAGR. Several companies, including Avant Technologies and Ainnova, are advancing FDA approvals for AI diagnostic tools, with Ainnova targeting 1,000 patients for diabetic retinopathy screening. Other firms like RadNet and Clover Health have also received FDA clearances for remote imaging and COPD management.PR NewswireHealthcare AI Market Explodes 38.5% Annually as Diagnostics Gain FDA TractionThe global AI healthcare market is forecast to reach nearly $700 billion by 2034, growing 38.5% annually. Several companies, including Avant Technologies and Ainnova, are advancing FDA approvals for AI diagnostics, with Ainnova targeting 1,000 diabetic patients for its Vision AI platform. Other firms like RadNet and Butterfly Network have also received FDA clearances for remote imaging and cardiac screening.PR NewswireAI Just Got a Green Light from the White House--Here's What That Means for Healthcare StocksThe U.S. Department of Commerce, as part of President Trump's AI Action Plan, is encouraging regulatory sandboxes to accelerate AI adoption in slow-moving sectors like healthcare. Avant Technologies and its joint-venture partner Ainnova Tech have finalized an updated clinical trial protocol for their AI-powered Vision AI platform following FDA feedback, with the protocol now under review by contract research organization Fortrea to support 510(k) clearance for early detection of diabetic retinopathy. The article also briefly highlights several other healthcare AI companies—Renovaro, Healthcare Triangle, GE HealthCare, and Spectral AI—making separate advancements in diagnostics, drug development, and workflow automation.FinansavisenAI Is Quietly Reinventing Healthcare--And Real Deployments Are Now UnderwayAvant Technologies and Ainnova Tech are preparing for a July 7 FDA pre-submission meeting for their Vision AI diabetic retinopathy screening platform, aiming for 510(k) clearance. The company also plans to launch a standalone diabetes treatment company and has begun offering free scans in pharmacy chains. Other AI health firms like Tempus, OmniAb, and Recursion are advancing diagnostics and drug discovery.PR NewswireNew AI Rollouts Signal Shift From Hype to Healthcare RealityMultiple healthcare AI companies are moving from theoretical applications to practical deployments, with Avant Technologies announcing plans to form a new company dedicated to developing a diabetes treatment through a potential joint venture, partnership, or acquisition of Ainnova Tech. Avant's Vision AI platform, which can detect diabetic retinopathy and other conditions through retinal scans, is being expanded into treatment development alongside free screenings at pharmacy chains in Mexico, while the company works toward streamlining its holding-company structure following a non-binding LOI to acquire 100% of Ainnova Tech ahead of an FDA pre-submission meeting in July.